Merck Expects Underlying Operating Expenses To Increase Mid- To High-Single Digits Next Year; For Keytruda Expecting Moderating Growth As We Approach Peak Revenues For Certain Approved Indications; For Keytruda, Expecting German Market To Be Impacted By Policy Dynamics; Expecting Keytruda & Winrevair Benefit To Fully Unwind In Q4; Majority Of Vaccines Benefit, Primarily Gardasil, To Unwind In 2027
https://www.merck.com/wp-content/uploads/sites/124/2026/10/3Q26-Merck-Earnings-Presentation.pdf
Share
Why It Matters
Merck says costs will go up next year, and some star medicines are slowing down. When a company says growth is moderating, it means watch whether new drugs can take over as older ones mature.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.